Siplizumab

From Wikipedia, the free encyclopedia

Siplizumab^?
Therapeutic monoclonal antibody
Source	Human
Target	?
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Siplizumab (MEDI-507) is a novel MAb with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.^[1]

[edit] References

^ Home - ClinicalTrials.gov

v • d • e Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04)

Monoclonal antibodies	TNF inhibitors (Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox

-imus	Abetimus, Deforolimus, Everolimus, Gusperimus, Pimecrolimus, Sirolimus, Tacrolimus, Temsirolimus, Zotarolimus

-cept (Fusion protein)	Abatacept, Aflibercept, Alefacept, Belatacept, Rilonacept, TNF inhibitor (Etanercept)

Other	Anakinra, Azathioprine, Ciclosporin, Leflunomide, Methotrexate, Mycophenolic acid, Thalidomide

v • d • e Humanized monoclonal antibodies ("-zu-")

"-tuzu-" (tumor)	Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin

"-lizu-" (immune system)	Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab

"-bazu-" (bacterial)	Tefibazumab

"-cizu-" (cardiovascular)	Bevacizumab, Tadocizumab

"-neuzu-" (nervous system)	Bapineuzumab

"-toxazu-" (toxin as target)	Urtoxazumab

"-vizu-" (viral infections)	Felvizumab, Motavizumab, Palivizumab, PRO 140